Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | CNR2 | P34972 | 8/20 | 0.69 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.67 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.56 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | CTSA | P10619 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956276 | 0.90 | CNR2 (0.65) | KMT2ACNR2UTS2RLMNAKEAP1 | |
| SCHEMBL27558113 | 0.90 | CNR2 (0.65) | KMT2ACNR2UTS2RLMNAKEAP1 | |
| SCHEMBL28760324 | 0.90 | CNR2 (0.65) | KMT2ACNR2UTS2RLMNAKEAP1 | |
| SCHEMBL6983179 | 0.85 | KMT2A (0.54) | KMT2ACNR2UTS2RSLC6A9LMNA | |
| SCHEMBL15064420 | 0.82 | CNR2 (1.00) | CNR2UTS2RCNR1 | |
| SCHEMBL7822835 | 0.79 | KDM4E (0.67) | UTS2RCTSA | |
| SCHEMBL7899003 | 0.79 | ALDH1A1 (0.74) | KMT2ACNR2UTS2RSLC6A9PSMB8 | |
| Hydrochloric Acid SCHEMBL5464562 | 0.79 | UTS2R (0.98) | CNR2UTS2R | |
| SCHEMBL2313693 | 0.79 | MME (0.66) | KMT2ACNR2PSMB8PSMB5 | |
| SCHEMBL2313700 | 0.79 | MME (0.66) | KMT2ACNR2PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610882-B2 | Affinity for bradykinin receptors; antithrombotics | SANOFI-SYNTHELABO (FR) | 2003-08-26 | — | — | US | disclosed |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2003-04-17 | — | — | US | disclosed |
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6433185-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
| US-6313120-B1 | TREATMENT OR PREVENTION OF DISEASES INVOLVING BRADYKININ RECEPTORS | SANOFI-SYNTHELABO (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6100278-A | COMPOUNDS HAVING AFFINITY FOR BRADYKININ RECEPTORS; ANTIINFLAMMATORY AGENTS | SANOFI-SYNTHELABO (FR) | 2000-08-08 | — | — | US | disclosed |
| US-6015812-A | N-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity | SANOFI-SYNTHELABO (FR) | 2000-01-18 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | KMT2A 4041/4885CNR2 376/4885UTS2R 1095/4885 |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | KMT2A 4041/4885CNR2 376/4885UTS2R 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.